BMRA

Business Context and Reporting Period

Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: November 30, 2025 (Six months ended November 30, 2025)
Business Overview: Biomerica is a global biomedical technology company developing, manufacturing, and marketing diagnostic and therapeutic products, primarily for gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates as a single segment with facilities in the U.S., Mexico, and Germany.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased by 25% ($854,000) compared to the prior year period. This was driven by lower clinical laboratory sales, reduced contract manufacturing billings, and a significant drop in Over-the-Counter (OTC) sales, particularly in the Middle East market.
• Cost of Sales: Cost of sales decreased by 22% ($607,000), primarily due to lower sales volumes and reduced inventory write-offs. However, the gross margin percentage contracted from 21.0% to 18.4%.
• Operating Expenses: Total operating expenses decreased slightly by 4% ($121,000). Selling, General, and Administrative (SG&A) expenses increased by 1% due to higher credit loss provisions and tax credit advisory fees, while Research and Development (R&D) expenses decreased by 27% due to reduced labor hours and sponsorship costs.
• Other Income: Other income surged by 1,116% to $1,180,000, primarily due to a one-time $1,100,000 refund received from the IRS related to the Employee Retention Credit (ERC). Excluding this non-recurring item, other income decreased.
• Net Loss Improvement: The net loss narrowed significantly to $(1,318,000) from $(2,266,000) in the prior year, largely attributable to the ERC refund.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. Current cash and cash equivalents are deemed insufficient to meet operating requirements and strategic growth objectives without additional financing.
• Liquidity Strategy: The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, and secure additional financing through debt or equity. During the period, the company raised approximately $1.4 million in net proceeds via an At-The-Market (ATM) offering.
• Product Outlook: Commercialization of key new products (inFoods® IBS and hp+detect™) has been slower than expected. The company is focusing on targeted gastroenterology practices for inFoods® IBS and pursuing Medicare reimbursement. A partnership with Henry Schein is being explored to enhance market reach.
• Risks: Key risks include the inability to raise additional capital, competition from larger entities, regulatory certification delays, and concentration of credit risk (one customer accounted for 39% of sales in the six-month period).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.54 million cash balance against the stated operating burn rate and the timeline for securing additional financing.
• Revenue Concentration: Assess the risk associated with the top customer in Asia, which accounted for 39% of net sales in the six-month period.
• Non-Recurring Income: Confirm that the $1.1 million ERC refund is a one-time event and does not reflect sustainable operational profitability.
• ATM Offering Capacity: Review the remaining capacity under the $5.5 million ATM offering and the $20 million shelf registration to understand future dilution potential.
• Inventory Reserves: Monitor the $434,000 inventory reserve and the trend in inventory write-offs given the decline in sales volumes.